Technology Innovation Institute Appoints Globally-Renowned Experts to Board of Advisors at Autonomous Robotics Research Centre
7.4.2021 13:30:00 EEST | Business Wire | Press release
Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today announced the appointment of leading international experts to the Board of Advisors at its Autonomous Robotics Research Centre (ARRC).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210407005504/en/
Dr. Najwa Aaraj, Acting Chief Researcher at Autonomous Robotics Research Centre (Photo: AETOSWire)
The appointments follow a series of rapid announcements at Technology Innovation Institute since the first Advanced Technology Research Council board meeting in August 2020.
Autonomous Robotics Research Centre is one of the initial seven specialised centres at the Technology Innovation Institute. Members of the new Board of Advisors are renowned experts in various fields of intelligent autonomy, autonomous systems and robotics, robotics and perception, among others. The Centre’s researchers are engaged in exploring the latest advances in robotics that will help build hybrid societies made up of biological and artificial systems. The distinguished Board of Advisors will guide efforts to develop breakthrough technologies that have global impact.
The Board of Advisors includes Prof. Ian F. Akyildiz, the Ken Byers Chair Professor, Director of the Broadband Wireless Networking Lab and Chair of the Telecommunications Group at the School of Electrical and Computer Engineering at the Georgia Institute of Technology in the United States; Prof. Luca Benini, Chair of Digital Circuits and Systems at the Department of Information Technology and Electrical Engineering of the Swiss Federal Institute of Technology (ETH) Zurich and Professor of Electronics at Italy’s University of Bologna; Prof. Marko Bertogna, Professor at the University of Modena and Reggio Emilia in Italy, where he leads the High-Performance Real-Time Systems Laboratory; Prof. A. E. Eiben, Professor of Artificial Intelligence (AI) and Collective Systems at the Vrije Universiteit Amsterdam in the Netherlands and Visiting Professor at the University of York in the UK; Prof. Giuseppe Loianno, Assistant Professor of Robotics and Perception at New York University in the United States, and Prof. Martin Saska, founder of the Multi-Robot Systems Group at the Department of Cybernetics of Czech Technical University in Prague.
Speaking about the new appointments, Dr Najwa Aaraj, Acting Chief Researcher at Autonomous Robotics Research Centre, said: “The board members will facilitate scientific collaborations that will enable verifiable, rigorous, systematic, and empirical scientific investigation and research in advanced technology, putting Abu Dhabi and the wider UAE in a prime position to shape future capabilities in autonomous robotics across all dimensions - air, land, water, underwater, and even in space.”
About Technology Innovation Institute (TII):
Technology Innovation Institute (TII) is the dedicated ‘applied research’ pillar of Advanced Technology Research Council (ATRC). TII is a pioneering global research and development centre that focuses on applied research and new-age technology capabilities. The Institute has seven initial dedicated research centres in quantum, autonomous robotics, cryptography, advanced materials, digital security, directed energy and secure systems. By working with exceptional talent, universities, research institutions and industry partners from all over the world, the Institute connects an intellectual community and contributes to building an R&D ecosystem reinforcing Abu Dhabi and the UAE’s status as a global hub for innovation.
For more information, visit www.tii.ae
About Autonomous Robotics Research Centre (ARRC):
Autonomous Robotics Research Centre (ARRC) – at Technology Innovation Institute (TII) – is dedicated to breakthrough developments in robotics and autonomy. With in-depth technical expertise in robotics, computer vision, and bio-inspired technologies, the Centre has established a leadership position in its field.
For more information, visit https://autonomousrobotics.tii.ae/
Connect with us on social media:
LinkedIn: https://www.linkedin.com/company/tiiuae/
Twitter: https://twitter.com/TIIuae
Instagram: https://www.instagram.com/tiiuae/
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407005504/en/
Contact information
Haitham Haddadin
Haitham.Haddadin@tii.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 11:15:00 EEST | Press release
Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easier to access, navigate and manage. This will ultimately give pet parents better guidance, greater confidence and more control at every point in
Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release
Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom